Showing 43,061 - 43,080 results of 49,954 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( a ((fold decrease) OR (point decrease)) ))', query time: 1.29s Refine Results
  1. 43061
  2. 43062
  3. 43063
  4. 43064

    Data_Sheet_1_Sleep duration and depression among adolescents: Mediation effect of collective integration.docx by Min Gao (87060)

    Published 2022
    “…The analytic sample in the present study included 8,829 seventh-grade students aged about 14 years (51.50% boys and 48.50% girls). A structural equation modeling (SEM) was used to investigate parent–child/teacher factors affecting adolescent sleep duration and depression, and Monte Carlo resampling with R was employed to confirm the significance of the mediation effects of collective integration. …”
  5. 43065
  6. 43066

    Table3_Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).DOCX by Ming-Tao Wen (16530297)

    Published 2024
    “…</p>Results<p>Out of 107,123 reports with teriparatide as the primary suspect, key AEs identified included pain in extremity (PRR: 4.54), muscle spasms (PRR: 5.11), fractures (PRR range: 17.67–552.95), and increased calcium levels (PRR: 50.73). Teriparatide exhibited a stronger association with increased calcium levels (PRR: 50.73) compared to fractures (PRR range: 17.67–552.95). …”
  7. 43067

    Table 1_Concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-γ autoantibodies.docx by Wan-Ting Tsai (492227)

    Published 2025
    “…</p>Methods<p>This study included 50 patients diagnosed with adult-onset immunodeficiency due to nAIGA between 2014-2024. …”
  8. 43068
  9. 43069
  10. 43070
  11. 43071
  12. 43072
  13. 43073

    Table4_Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).DOCX by Ming-Tao Wen (16530297)

    Published 2024
    “…</p>Results<p>Out of 107,123 reports with teriparatide as the primary suspect, key AEs identified included pain in extremity (PRR: 4.54), muscle spasms (PRR: 5.11), fractures (PRR range: 17.67–552.95), and increased calcium levels (PRR: 50.73). Teriparatide exhibited a stronger association with increased calcium levels (PRR: 50.73) compared to fractures (PRR range: 17.67–552.95). …”
  14. 43074
  15. 43075
  16. 43076
  17. 43077
  18. 43078
  19. 43079
  20. 43080

    Table7_Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).DOCX by Ming-Tao Wen (16530297)

    Published 2024
    “…</p>Results<p>Out of 107,123 reports with teriparatide as the primary suspect, key AEs identified included pain in extremity (PRR: 4.54), muscle spasms (PRR: 5.11), fractures (PRR range: 17.67–552.95), and increased calcium levels (PRR: 50.73). Teriparatide exhibited a stronger association with increased calcium levels (PRR: 50.73) compared to fractures (PRR range: 17.67–552.95). …”